Global Recombinant DNA Technology Market - 2020-2027
発行: DataM Intelligence
Recombinant DNA technology includes the insertion of the DNA into the genome with the gene of interest. It produces the new genetic combinations by joining the DNA molecules from two different species and inserted into the host organism. New genetic combination includes the genetic material from multiple sources that is not found in the genome. It results in production of the genetically modified organisms and products. The genetically modified organisms such as microorganisms, animals, and plants have showed the enhanced product yield, and increased adaptability for better survival.
Several companies are using the recombinant DNA technology for producing the insulin, follistim, human growth hormones, monoclonal antibodies, human albumin, vaccines, gene therapy and other therapeutics. It is also used for producing the genetically modified crops, cloned animals, bio pesticides, biofuel, and other products.
The global recombinant dna technology market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Technology Advancement of Recombinant DNA Technology is Driving the Growth of the Market
The market is witnessing the technological advancement for developing the efficient diagnostic tools and therapeutics. The introduction of the Bac-to-Bac baculovirus expression systems had provided the efficient method to produce recombinant baculovirus with desired genes in insect cells. Bac-to-Bac baculovirus expression systems has accelerated the cloning reaction in comparision to the restriction enzyme cloning that consumes lot of time. CRISPR technology can alter DNA sequences and modify gene function. It is used in various applications such as orrecting genetic defects, treating and preventing the spread of diseases and improving crops. There is increasing adoption of the germline gene therapy to transfer the DNA into the cells that produce reproductive cells, eggs or sperm, in the body. This therapy is beneficial for correction of disease-causing gene variants that can be passed from the generation to the generation. Somatic gene therapy is used for transfering the DNA into the body tissues. It targets the body cells that are not passed from the generation to the generation.
Increasing Funding & Investment for Development of Recombinant Products is Expected to Fuel the Market Growth over the Forecast Period
Several organizations, associations, and institutes are raising the funding & investment for the development of the recombinant products. For instance, in March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI), had invested USD 4.4 million in collaboration agreements with Novavax, Inc. and The University of Oxford to rapidly develop recombinant vaccine products against COVID-19. Under the terms of agreement, CEPI would provide initial funding to Novavax to enable preparations for phase I trials. The University of Oxford would support the manufacture of vaccine materials required for preclinical and phase I testing. In July 2020, the United States Departments of Health and Human Services (HHS) and Defense (DoD) had awarded the funding of USD 2.1 billion to Sanofi and GlaxoSmithKline for the development and manufacturing of the recombinant protein-based COVID-19 vaccine. Health and Human Services (HHS) and Defense (DoD) would provide the funding as part of Operation Warp Speed.
Ethical Issues Regarding the Use of Recombinant Products is Hampering the Market Growth
There are several ethical issues are associated with the use of recombinant products. There are several concerns including whether the recombinant products is biologically equivalent to the natural product, and recombinant proteins can result in immunogenic reactions that could limit their use. The use of the recombinant product is tampering with the genome. Differences in immunological sensitivities in animal and human systems have demonstrated the disastrous effects. TeGenero trial conducted for testing an antibody TGN1412 among the patients with rheumatoid arthritis and B-cell chronic lymphocyte leukemia has shown the harmful effects. Germ-cell gene therapy would ultimately diminish the human gene pool by removing genes considered to be bad. Only rich people would be benefited due to the high cost of the gene therapy. The widespread use of the gene therapy can make the society to least accept the people who are different. There are also ethical concerns regarding the use of the gene therapy for enhancing the basic human traits such as height, intelligence, or athletic ability.
COVID-19 Impact Analysis
The global recombinant dna technology market has witnessed the drastic growth due to the COVID-19 pandemic as the several biopharmaceutical companies are focussing in developing the vaccine by using the recombinant DNA technology for the prevention of COVID-19. There is increasing research and development activities for development of the recombinant vaccine for COVID-19 with the rising number of people being affected by the COVID-19 infection. The pipeline comprised of the several viral vector, nucleic acid-based vaccines and antigen-presenting cells being developed for COVID-19. Viral vector vaccines comprised of the recombinant virus that is attenuated to reduce its pathogenicity, and genes encoded with viral antigen are cloned using the recombinant DNA techniques. Protein-based vaccines comprised of the protein purified from the virus or virus-infected cells, recombinant protein or virus-like particles
Several organizations, associations, institutes, and companies are entering into the collaboration for the development of recombinant vaccine for COVID-19 infection. For instance, in April 2020, Sanofi had entered into the collaboration with GlaxoSmithKline plc to develop an adjuvanted vaccine for COVID-19. Under the terms of agreement, Sanofi would contribute its S-protein COVID-19 antigen based on recombinant DNA technology. GlaxoSmithKline plc would contribute its proven pandemic adjuvant technology. This may be useful to produce the more vaccine doses with the reduced amount of vaccine protein required per dose and thus protect more people.
Chronic diseases are the leading cause of mortality and morbidy worldwide. According to the Centers for Disease Control and Prevention (CDC), around, 6 out of 10 adults are suffering from the chronic diseases. Approximately, 4 out of 10 people develop two or more chronic diseases. Heart disease, cancer, chronic lung disease, stroke, alzheimer's disease, diabetes, and chronic kidney disease are the most common chronic diseases. Tobacco consumption, poor nutrition, lack of physical activity, excessive alcohol use, and other disorders increase the risk of developing the chronic diseases. According to the American Diabetes Association, the approximately 34.2 million are suffering from the diabetes in the United States. Out of these people, around 1.6 million are affected by type 1 diabetes.
Medical segment is expected to hold the largest share in the Recombinant DNA Technology market
By Product Type, the medical segment is anticipated to hold the largest share in the recombinant DNA technology treatment market owing to the higher adoption of the recombinant DNA technology for the production of the pharmaceutical products. Recombinant DNA technology is used for producing the novel pharmaceutical products, safer or more effective versions of conventionally produced pharmaceuticals, and substances identical to conventionally made pharmaceuticals. The medical segment is classified as the therapeutic agent, human protein, and vaccine. The recombinant DNA technology is used to produce the human proteins that can be used as the diagnostic tools and therapeutics for the treatment of the various genetically linked diseases. Various recombinant proteins such as recombinant hormones, interferons, interleukins, growth factors, tumor necrosis factors, blood clotting factors, thrombolytic drugs, and enzymes are useful for the treatment of the diseases such as diabetes, dwarfism, myocardial infarction, congestive heart failure, cerebral apoplexy, multiple sclerosis, neutropenia, thrombocytopenia, anemia, hepatitis, rheumatoid arthritis, asthma, Crohn's disease, and others. Vaccines produced by using the recombinant DNA technology are based on the expression of biological constructs encoding proteins from specific viral pathogens. These vaccines are made of protein or glycoprotein subunits synthesized in the laboratory.
Expression System Segment is Anticipated to Grow at the Fastest Growth Rate over the Forecast Period
By component, the market is segmented into expression system and cloning vector. Expression systems are essential for expressing the proteins within the chosen host cell. There is increasing development of the efficient protein expression systems at a large scale across the globe. The market is dominated by the availability of the several expression systems such as bacteria expression system, yeast expression system, baculovirus expression system and mammalian expression system. The choice fo the expression systems depend on the various factors such as target protein property, intended application, protein yield and cost. Yeast expression system is the new exogenous protein expression system that contains the characteristics from both prokaryotic and eukaryotic expression system. There is high usage of the yeast expression system in genetic engineering. The recombinant proteins expressed in mammalian cell expression system includes the use of plasmid transfection and viral vector infection. There is increasing research for evaluating the potential of plant as the expression system for the production of genetic modified products.
North America region holds the largest market share global Recombinant DNA Technology market
North America region is dominating the global recombinant DNA technology market accounted for the largest market share in 2019 due to higher adoption of the recombinant DNA technology in medicines, agriculture, industries, and research. There is increasing usage of the recombinant DNA technology for the prevention, treatment, and management of diseases with the increasing prevalence of the chronic diseases. The United States accounts for the highest market share due to the presence of the large number of the biopharmaceutical manufacturing companies. There is rising usage of the advanced recombinant DNA technologies for the development of the veterinary products, genetically modified crops, and biopesticides. Researchers are also using the recombinant DNA technology to alter the biomass for improving its use for biofuel production.
There is increasing research and development activities for biopharmaceuticals. Several companies are entering into the collaboration with the institutes, organizations, and associations for developing the biopharmaceuticals. For instance, in February 2020, Sanofi had entered into the collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a component of United States Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response for the development of the recombinant vaccine for novel coronavirus. Under the terms of agreement, Sanofi would use its egg-free, recombinant DNA platform to produce a vaccine for novel coronavirus. BARDA would provide the expertise and reallocated funds to support the vaccine's development. In December 2019, Sanofi had entered into the collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to establish state of the art facilities in the United States for the production of an adjuvanted recombinant vaccine for influenza pandemic.
Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period
Asia-Pacific region is estimated to be the fastest-growing region in the global recombinant DNA technology market as there is increase in the number of the market players developing the recombinant DNA technology products. Several companies are shifting their manufacturing base to the Asia-Pacific region due to the availability of the skilled and cheap laborers. There is rising demand for the recombinant and genetically modified products for human health, food and agriculture.
Companies are focusing on improving the recombinant DNA technology for the production of the genetically modified crops to increase the crop yields, reduced costs for food or drug production, reduced need for use of pesticides, enhanced nutrient composition and food quality, resistance to pests and disease. There is growing penetration of the recombinant DNA technology for providing the selective improvements in pharmaceutics, gene therapy, vaccine design and bioremediation. Several organizations, associations, and institutes are raising the funding & investment for use of recombinant DNA technology for healthcare, food and agriculture.
The recombinant DNA technology market studied is a fragmented market with the presence of large number of market players. F. Hoffmann-La Roche Ltd, Biogen, Amgen Inc, Novartis AG, Eli Lilly and Company, Pfizer Inc., Novo Nordisk A/S, Sanofi, Merck KGaA, GlaxoSmithKline plc., and Thermo Fisher Scientific, Inc are the market players with the significant market share. The major players are adopting several growth strategies such as product launches, product approvals, mergers, licensing, acquisitions, and collaborations, which are contributing to the growth of the recombinant dna technology market globally. For instance,
The global Recombinant DNA Technology market report would provide an access to an approx. 61 market data table, 58 figures and 230 pages.
LIST NOT EXHAUSTIVE